Celgene Corporation (CELG) : Webster Bank N. A. reduced its stake in Celgene Corporation by 0.23% during the most recent quarter end. The investment management company now holds a total of 4,428 shares of Celgene Corporation which is valued at $436,158 after selling 10 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Oct 14, 2016.Celgene Corporation makes up approximately 0.06% of Webster Bank N. A.’s portfolio.
Other Hedge Funds, Including , Creative Planning boosted its stake in CELG in the latest quarter, The investment management firm added 4,855 additional shares and now holds a total of 75,757 shares of Celgene Corporation which is valued at $7,699,941. Celgene Corporation makes up approx 0.05% of Creative Planning’s portfolio. Eagle Asset Management Inc added CELG to its portfolio by purchasing 18,970 company shares during the most recent quarter which is valued at $1,928,111. Celgene Corporation makes up approx 0.01% of Eagle Asset Management Inc’s portfolio.Central Bank Trust Co reduced its stake in CELG by selling 5,752 shares or 6.55% in the most recent quarter. The Hedge Fund company now holds 82,121 shares of CELG which is valued at $8,546,332. Celgene Corporation makes up approx 2.43% of Central Bank Trust Co’s portfolio. Lenox Wealth Advisors added CELG to its portfolio by purchasing 25 company shares during the most recent quarter which is valued at $2,632.
Celgene Corporation closed down -2.13 points or -2.12% at $98.5 with 43,17,515 shares getting traded on Friday. Post opening the session at $101.25, the shares hit an intraday low of $98.48 and an intraday high of $101.389 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.